The company says the IVD 2020 market is really extensive and growing, even before it hit the COVID-19 pandemic. Now, the COVID-19 pandemic has particularly shaped the market, adding $9 billion to revenue.
COVID-19 PCR outdoor growth spaces and antibody tests come with other infectious diseases (i.e. respiratory pathogens), liquid biopsies, other major diagnoses, and hematology and intensive care tests. d-Dimer is not a domain that is not included in the old Kalorama IVD totals that were added in this edition, it used to stumble upon the severity of COVID cases. All intensive care tests, namely blood gases, PCT and other biomarkers, were well performed.
Check the content to download the media: https://www.prnewswire.com/news-releases/ivd-market-reaches-83-billion-says-new-report-301120941.html
SOURCE Information about Kalorama